Global CDMO honored for Growth in Mammalian, Microbial and Cell and Gene Manufacturing capabilities at Seattle, Boulder and Longmont sites
AGC Biologics Named Manufacturing Company of the Year by American Business Awards
Nick McDonald Published on 6/29/22 6:00 AM News
Learn More
AGC Biologics Provides Aid to Ukraine
Nick McDonald Published on 5/11/22 2:01 PM News
AGC Biologics is deeply concerned and grieved about the situation in Ukraine. We sincerely hope that peaceful life will return to everyone as soon as possible. We also stand in partnership with our parent company, AGC Inc., in providing support for the safety and wellbeing of our Ukrainian colleagues and their families.
Allergy Therapeutics Selects AGC Biologics to Manufacture Peanut Allergy Vaccine Candidate
Nick McDonald Published on 3/31/22 6:00 AM News
AGC Biologics
is producing vaccine materials for early-stage product trials at its Heidelberg facilities
AGC Biologics Supports BioNTech Omicron-based Vaccine Candidate with pDNA Starting Material
Press Release Published on 2/8/22 4:00 PM News, Company News, Partnership
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
AGC Biologics Names Regina Choi-Rivera General Manager of Boulder Facility
Press Release Published on 1/18/22 1:15 PM News, Company News
AGC Biologics today announced Regina Choi-Rivera as the new General Manager of the company’s large-scale biopharmaceutical mammalian production facility in Boulder. In this role, she assumes executive oversight and leadership and will manage strategic development and facility operations.
I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project
Nick McDonald Published on 12/13/21 5:00 PM News
AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, while also supporting the launch readiness of I-MAB’s product.
AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry
Nick McDonald Published on 12/7/21 10:39 AM News
AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.
4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab
Press Release Published on 12/1/21 6:03 AM News, Company News
AGC Biologics to produce Procizumab for early and late clinical Phases at the company’s Chiba and Copenhagen facilities
AGC Biologics Appoints Jean-Baptiste Agnus as Chief Business Officer
Press Release Published on 11/1/21 6:00 AM News
SEATTLE – November 1, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced Jean-Baptiste Agnus has been appointed as the company’s Chief Business Officer (CBO). In this position, he is responsible for strategic leadership over all aspects of the company’s global business development and sales and marketing teams.
AGC Biologics Expands pDNA and mRNA Manufacturing Capacity
Nick McDonald Published on 9/13/21 5:00 PM News
Seattle – September 13, 2021 – AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
Follow Us
